ARS Pharmaceuticals' Neffy Nasal Spray Approved by FDA for Type I Allergic Reactions (2024)

Market Closed - Nasdaq Other stock markets 21:00:00 09/08/2024 BST			5-day change	1st Jan Change
10.88 ^USD	+10.01%		+9.90%	+98.54%

08-09	ARS Pharmaceuticals' Neffy Nasal Spray Approved by FDA for Type I Allergic Reactions	MT
08-09	ARS Pharmaceuticals, Inc. Receives FDA Approval of Neffy® (Epinephrine Nasal Spray), the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis	CI

Summary

Quotes

Charts

News

Company

Financials

Valuation

Consensus

Calendar

Latest news about ARS Pharmaceuticals, Inc.

ARS Pharmaceuticals' Neffy Nasal Spray Approved by FDA for Type I Allergic Reactions	08-09	MT
ARS Pharmaceuticals, Inc. Receives FDA Approval of Neffy® (Epinephrine Nasal Spray), the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis	08-09	CI
FDA Approves ARS Pharma's Neffy Nasal Spray for Emergency Allergy Treatment	08-09	DJ
U.S. FDA approves first nasal spray for allergic reactions	08-09	RE
ARS Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	08-06	CI
Asahi Songwon Colors Appoints CFO	07-29	MT
Asahi Songwon Colors Limited Announces Chief Financial Officer Changes	07-27	CI
Raymond James Starts ARS Pharmaceuticals With Outperform Rating	07-25	MT
Ars Pharmaceuticals Insider Sold Shares Worth $961,725, According to a Recent SEC Filing	07-11	MT
Ars Pharmaceuticals Insider Sold Shares Worth $961,725, According to a Recent SEC Filing	07-11	MT
ARS Pharmaceuticals, Inc.(NasdaqGM:SPRY) dropped from Russell 3000E Value Index	06-30	CI
ARS Pharmaceuticals, Inc.(NasdaqGM:SPRY) dropped from Russell 2000 Value Index	06-30	CI
ARS Pharmaceuticals, Inc.(NasdaqGM:SPRY) dropped from Russell 3000 Value Index	06-30	CI
ARS Pharmaceuticals, Inc.(NasdaqGM:SPRY) dropped from Russell 2500 Value Index	06-30	CI
ARS Pharmaceuticals, Inc.(NasdaqGM:SPRY) dropped from Russell Microcap Value Index	06-30	CI
ARS Pharmaceuticals, Inc.(NasdaqGM:SPRY) dropped from Russell Small Cap Comp Value Index	06-30	CI
ARS Pharmaceuticals' Adrenaline Nasal Spray Receives EMA Committee's Positive Opinion	06-28	MT
EU regulator recommends approval for ARS pharma's nasal spray alternative to EpiPen	06-28	RE
ARS Pharmaceuticals, Inc. Announces EURneffy (Adrenaline Nasal Spray) Recommended for Approval by CHMP for Emergency Treatment of Allergic Reactions (Anaphylaxis)	06-28	CI
Ars Pharmaceuticals Insider Sold Shares Worth $913,917, According to a Recent SEC Filing	06-13	MT
ARS Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09	CI
ARS Pharmaceuticals, Inc. Submits Response for Neffy (Epinephrine Nasal Spray) Marketing Authorization Application to EMA's Chmp	04-30	CI
Ars Pharmaceuticals, Inc. Enters Exclusive License and Distribution Agreement with CSL Seqirus for Commercialization of Neffy in Australia and New Zealand	04-30	CI
ARS Pharmaceuticals Insider Sold Shares Worth $928,005, According to a Recent SEC Filing	04-18	MT
ARS Pharmaceuticals Insider Sold Shares Worth $928,005, According to a Recent SEC Filing	04-18	MT

Chart ARS Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

ARS Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing neffy, for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, administered and nasal spray. Type I allergic reactions are potentially life-threatening hypersensitivity reactions that can occur within minutes of exposure to an allergen and need to be treated immediately to relieve symptoms and prevent further progression.

Employees

Sector

Calendar

06/11/2024 - Q3 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement and Estimates

More financial data

Ratings

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

10.88USD

Average target price

19.00USD

Spread / Average Target

+74.63%

Consensus

Profit revisions

Estimate revisions

Quarterly earnings, Rate of surprise

Company calendar

Stock Market
Equities
SPRY Stock
News ARS Pharmaceuticals, Inc.
ARS Pharmaceuticals' Neffy Nasal Spray Approved by FDA for Type I Allergic Reactions

Our Free Content Help you Secure and Increase the Performance of Your Investments Secure my Investments

"); for (var element in ICConf) { if (document.getElementById("zpp"+element)) { document.getElementById("zpp"+element).innerHTML = ""; } } InvestingChannelQueue.push(function() { ic_page = InvestingChannel.UAT.Run("5c5a75c3-8896-4592-98f8-dc06e6fdcc56"); }); } gaEvent('adspv', 'InvestingChannel_v2', 'US');googletag.cmd.push(function() { googletag.pubads().setTargeting('Edition', 'en_GB');googletag.pubads().setTargeting('UserType', 'free');googletag.pubads().setTargeting('Content', 'equities');googletag.pubads().setTargeting('codezb', '116155892');googletag.enableServices();googletag.pubads().collapseEmptyDivs();try{googletag.pubads().getSlots().forEach(function(slot){if(slot.getSlotElementId().startsWith('zpp')){;}else{googletag.pubads().refresh([slot],{changeCorrelator: false});}})}catch(error){console.error(error)}});$(document).ready(function() { $( document).on('zbv_visible',function () {startAdsService();}); if (document[zbv_hidden]===false) { startAdsService(); } });